Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin or pre-B-cell colony-enhancing factor (PBEF), is the rate-limiting enzyme in the mammalian nicotinamide adenine dinucleotide (NAD+) salvage pathway, converting nicotinamide to nicotinamide mononucleotide (UniProt P43490). It exists in two distinct forms: intracellular NAMPT (iNAMPT), which maintains the NAD+ pool required for mitochondrial function and DNA repair, and extracellular NAMPT (eNAMPT), which acts as a pro-inflammatory adipokine. NAMPT is frequently overexpressed in various malignancies, including colorectal, ovarian, and breast cancers, to support the high metabolic and DNA repair demands of tumor cells. Consequently, NAMPT is a significant therapeutic target in oncology, with small-molecule inhibitors like FK866 and KPT-9274 designed to induce metabolic collapse and apoptosis through NAD+ depletion. Beyond oncology, its role in inflammatory signaling links it to conditions such as rheumatoid arthritis and metabolic syndrome, though clinical development of inhibitors has been challenged by dose-limiting toxicities like thrombocytopenia.
Competitive or non-competitive inhibition of the NAMPT enzyme, which prevents the conversion of nicotinamide to nicotinamide mononucleotide, thereby depleting cellular NAD+ pools and inducing metabolic collapse.
4 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinamide phosphoribosyltransferase (NAMPT) (NAMPT).